Stockscreener 앱 받기
0.4439
3.30%
0.0142
Invivyd Inc 주식(IVVD)의 최신 뉴스
Charles Schwab Investment Management Inc. Sells 289,312 Shares of Invivyd, Inc. (NASDAQ:IVVD) - Defense World
Insider Selling: Invivyd, Inc. (NASDAQ:IVVD) Director Sells 74,764 Shares of Stock - MarketBeat
Invivyd director Terrance McGuire sells shares worth $147,795 By Investing.com - Investing.com South Africa
Invivyd director Terrance McGuire sells shares worth $147,795 - Investing.com
Invivyd, Inc. (NASDAQ:IVVD) Director Sells $30,718.73 in Stock - MarketBeat
Invivyd director Terrance McGuire sells $103,384 in stock - Investing.com
Adagio Therapeutics Stock Hits 52-Week Low at $0.57 Amid Challenges - Investing.com
Fmr LLC Sells 1,046,775 Shares of Invivyd, Inc. (NASDAQ:IVVD) - Defense World
Fmr LLC Decreases Stock Holdings in Invivyd, Inc. (NASDAQ:IVVD) - MarketBeat
Invivyd announces board member resignation By Investing.com - Investing.com South Africa
Invivyd announces board member resignation - Investing.com
Analysts Provide An Important Insights On Invivyd Inc (IVVD) - Stocks Register
Invivyd's (IVVD) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
HC Wainwright Cuts Invivyd (NASDAQ:IVVD) Price Target to $10.00 - Defense World
FY2024 Earnings Forecast for Invivyd Issued By HC Wainwright - Defense World
Adagio Therapeutics stock hits 52-week low at $0.72 By Investing.com - Investing.com Australia
Adagio Therapeutics stock hits 52-week low at $0.72 - Investing.com
Invivyd, Inc. (IVVD) Reports Q3 Loss, Misses Revenue Estimates - MSN
Invivyd (NASDAQ:IVVD) Given New $10.00 Price Target at HC Wainwright - MarketBeat
Invivyd, Inc. (NASDAQ:IVVD) Short Interest Up 15.8% in October - MarketBeat
Invivyd, Inc. (NASDAQ:IVVD) Q3 2024 Earnings Call Transcript - Insider Monkey
Invivyd Inc (IVVD) Quarterly 10-Q Report - Quartzy
Invivyd’s Q3 2024: Revenue Growth and Strategic Developments - TipRanks
Earnings call: Invivyd reports steady growth amid regulatory challenges - Investing.com
IVVD stock touches 52-week low at $0.81 amid market challenges - Investing.com India
Invivyd earnings missed by $0.18, revenue fell short of estimates - Investing.com Canada
Invivyd, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights - The Manila Times
Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor - The Manila Times
Invivyd's PEMGARDA Shows Promise Against COVID Variants Despite Lab Data Dispute | IVVD Stock News - StockTitan
Invivyd Inc (IVVD) Q3 2024 Earnings Report Preview: What to Expect - Yahoo Finance
Invivyd Inc (IVVD) Q3 2024 Earnings Report Preview: What to Expe - GuruFocus.com
Invivyd (IVVD) Set to Announce Earnings on Thursday - Defense World
FMR LLC's Strategic Reduction in Invivyd Inc Shares - GuruFocus.com
Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Upload - The Manila Times
Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term - The Bakersfield Californian
Invivyd's COVID Drug Shows 84% Risk Reduction in Phase 3 Trial, Secures FDA Authorization | IVVD Stock News - StockTitan
Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference - The Manila Times
Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference - GlobeNewswire Inc.
Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024 - The Manila Times
Invivyd (IVVD) Sets Q3 2024 Earnings Call: Financial Results & Business Updates Coming Nov 14 | IVVD Stock News - StockTitan
EF Hutton Initiates Coverage of Invivyd (IVVD) with Buy Recommendation - MSN
Invivyd (NASDAQ:IVVD) Upgraded at EF Hutton Acquisition Co. I - Defense World
Invivyd (NASDAQ:IVVD) Upgraded by EF Hutton Acquisition Co. I to "Strong-Buy" Rating - MarketBeat
Invivyd reports preliminary Q3 PEMGARDA product revenue $9.3M - MSN
This NANO Nuclear Energy Analyst Begins Coverage On A Bullish Note; Here Are Top Initiations For Wednesday - Benzinga
HC Wainwright Reiterates "Buy" Rating for Invivyd (NASDAQ:IVVD) - MarketBeat
Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Part - The Manila Times
Invivyd, Inc. Withdraws Financial Guidance for the Year 2024 - Marketscreener.com
2.88%
2.65%
자본화:
|
볼륨(24시간):